minoxidil has been researched along with Adverse Drug Event in 12 studies
Minoxidil: A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371)
minoxidil : A pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cetirizine is an antihistamine that may be effective in hair loss treatment." | 7.30 | Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. ( Abbassi, MM; Bassiouny, EA; El-Samanoudy, SI; Farid, SF; Nada, HR, 2023) |
| "Recent studies are promising for the intradermal delivery of dutasteride and minoxidil in the treatment of androgenetic alopecia." | 4.31 | Intradermal Delivery of Alopecia Therapeutics: Current State and Future Prospects. ( Alhanshali, L; Buontempo, M; Lo Sicco, K; Majerson, D; Shapiro, J, 2023) |
| "Minoxidil (2,4-diamino-6-(piperidin-1'-yl)pyrimidine N(3)-oxide; CASRN 38304-91-5) is a bioactive molecule with several nitrosatable groups widely used as an antihypertensive and antialopecia agent." | 3.77 | Aromatic C-nitrosation of a bioactive molecule. Nitrosation of minoxidil. ( Arenas-Valgañón, J; Calle, E; Casado, J; González-Jiménez, M, 2011) |
| "Cetirizine is an antihistamine that may be effective in hair loss treatment." | 3.30 | Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. ( Abbassi, MM; Bassiouny, EA; El-Samanoudy, SI; Farid, SF; Nada, HR, 2023) |
| " However, little is known about the differences in adverse effects between these two drugs." | 1.43 | Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases. ( Li, Q; Wu, M; Yu, Q, 2016) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 4 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Chen, M | 1 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 2 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Bassiouny, EA | 1 |
| El-Samanoudy, SI | 1 |
| Abbassi, MM | 1 |
| Nada, HR | 1 |
| Farid, SF | 1 |
| Alhanshali, L | 1 |
| Buontempo, M | 1 |
| Majerson, D | 1 |
| Shapiro, J | 1 |
| Lo Sicco, K | 1 |
| Legiawati, L | 1 |
| Suseno, LS | 1 |
| Sitohang, IBS | 1 |
| Yusharyahya, SN | 1 |
| Pawitan, JA | 1 |
| Liem, IK | 1 |
| Kurniawati, T | 1 |
| Ardelia, A | 1 |
| Paramastri, K | 1 |
| Beach, RA | 1 |
| McDonald, KA | 1 |
| Barrett, BM | 1 |
| Abdel-Qadir, H | 1 |
| Wu, M | 1 |
| Yu, Q | 1 |
| Li, Q | 1 |
| González-Jiménez, M | 1 |
| Arenas-Valgañón, J | 1 |
| Calle, E | 1 |
| Casado, J | 1 |
| Bergstrom, KG | 1 |
2 trials available for minoxidil and Adverse Drug Event
| Article | Year |
|---|---|
Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study.
Topics: Administration, Topical; Alopecia; Cetirizine; Drug-Related Side Effects and Adverse Reactions; Fema | 2023 |
Combination of adipose-derived stem cell conditioned media and minoxidil for hair regrowth in male androgenetic alopecia: a randomized, double-blind clinical trial.
Topics: Adipocytes; Alopecia; Culture Media, Conditioned; Drug-Related Side Effects and Adverse Reactions; H | 2023 |
10 other studies available for minoxidil and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Intradermal Delivery of Alopecia Therapeutics: Current State and Future Prospects.
Topics: Alopecia; Drug-Related Side Effects and Adverse Reactions; Dutasteride; Humans; Mesotherapy; Minoxid | 2023 |
Side effects of low-dose oral minoxidil for treating alopecia.
Topics: Administration, Oral; Alopecia; Drug-Related Side Effects and Adverse Reactions; Humans; Minoxidil | 2021 |
Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases.
Topics: 5-alpha Reductase Inhibitors; Adverse Drug Reaction Reporting Systems; Alopecia; Drug-Related Side E | 2016 |
Aromatic C-nitrosation of a bioactive molecule. Nitrosation of minoxidil.
Topics: Alopecia; Animals; Antihypertensive Agents; Chromatography, Liquid; Dimethylnitrosamine; Drug-Relate | 2011 |
What's new in androgenetic alopecia: approvals, long-term safety data, cancer risk and treatment options for women.
Topics: Alopecia; Azasteroids; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Dutasteride; | 2011 |